127956-11-0

Basic information

• Product Name: Methyl tetrahydro-4H-pyran-4-one-3-carboxylate
• Synonyms: Methyl tetrahydro-4H-pyran-4-one-3-carboxylate;Methyl 4-oxotetrahydro-2H-pyran-3-carboxylate;Methyl tetrahydro-4H-pyran-4-one-3-carboxylate-4;4-Oxotetrahydropyran-3-carboxylic acid methyl ester;2H-Pyran-3-carboxylic acid, tetrahydro-4-oxo-, methyl ester
• CAS NO: 127956-11-0
• Molecular Formula: C₇H₁₀O₄
• Molecular Weight: 158.1519
• Mol File: 127956-11-0.mol

Chemical Properties

• Boiling Point: 236.4±30.0 °C(Predicted)
• Appearance: /
• Density: 1.201±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 10.61±0.20(Predicted)
• CAS DataBase Reference: Methyl tetrahydro-4H-pyran-4-one-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl tetrahydro-4H-pyran-4-one-3-carboxylate(127956-11-0)
• EPA Substance Registry System: Methyl tetrahydro-4H-pyran-4-one-3-carboxylate(127956-11-0)

Safety Data

• Hazardous Substances Data: 127956-11-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Methyl tetrahydro-4H-pyran-4-one-3-carboxylate is used as a pharmaceutical intermediate for the synthesis of various drugs. Its carboxylate group allows for the formation of ester linkages, which are essential in the development of new pharmaceutical compounds. This intermediate is particularly useful in the creation of molecules with specific biological activities, contributing to the advancement of drug discovery and development.
As a pharmaceutical intermediate, Methyl tetrahydro-4H-pyran-4-one-3-carboxylate plays a crucial role in the synthesis of a wide range of therapeutic agents, including those targeting various diseases and conditions. Its versatility and reactivity make it a valuable component in the development of innovative medications, ultimately contributing to improved healthcare solutions.

Synthesis

Methyl 4-oxotetrahydro-2H-pyran-3-carboxylate was synthesized by reacting tetrahydropyranone with dimethyl carbonate in the presence of TEA.

Upstream product

• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 616-38-6 carbonic acid dimethyl ester 
• 17640-15-2 methyl cyanoformate 
• 94102-60-0 4-oxa-1,7-heptanedioic acid dimethyl ester 

Downstream Products

• 1447818-84-9 (S)-methyl 4-oxo-3-((S)-1-phenylallyl)tetrahydro-2H-pyran-3-carboxylate 
• 1418131-92-6 2-[((R)-1-phenyl-ethylamino)-methyl]-3,5,7,8-tetrahydro-pyrano[4,3-d]pyrimidin-4-one 
• 1419953-91-5 2-((4-fluorobenzylamino)methyl)-7,8-dihydro-3H-pyrano[4,3-d]pyrimidin-4(5H)-one 
• 1419953-30-2 C₂₄H₂₉FN₄O₅ 
• 1419953-25-5 C₂₃H₂₇ClN₄O₅ 
• 1419953-20-0 C₂₄H₃₀N₄O₅ 
• 1419953-05-1 C₂₄H₃₀N₄O₆ 
• 1419951-13-5 C₂₃H₂₆N₆O₄ 
• 1419949-96-4 N-(cyclopropylmethyl)-2-(4-(4-fluorobenzoyl)piperidin-1-yl)-N-((4-oxo-4,5,7,8-tetrahydro-3H-pyrano[4,3-d]pyrimidin-2-yl)methyl)acetamide 
• 1419949-20-4 N-(cyclopropylmethyl)-2-(4-(4-methoxybenzoyl)piperidin-1-yl)-N-((4-oxo-4,5,7,8-tetrahydro-3H-pyrano[4,3-d]pyrimidin-2-yl)methyl)acetamide 
• 1419949-16-8 C₃₀H₃₃FN₄O₄ 
• 1419949-12-4 C₂₅H₃₂N₄O₅ 
• 1419949-08-8 C₂₂H₂₅ClN₄O₄ 
• 1419949-04-4 2-(4-(4-fluorobenzoyl)piperidin-1-yl)-N-((4-oxo-4,5,7,8-tetrahydro-3H-pyrano[4,3-d]pyrimidin-2-yl)methyl)acetamide 

Relevant articles and documents

Discovery of a new class of valosine containing protein (VCP/P97) inhibitors for the treatment of non-small cell lung cancer

Valosine containing protein (VCP/p97) is a member of the AAA ATPase family involved in several essential cellular functions and plays an important role in the ubiquitin-mediated degradation of misfolded proteins. P97 has a significant role in maintaining the cellular protein homeostasis for tumor cell growth and survival and has been found overexpressed in many tumor types. No new molecule entities based on p97 target were approved in clinic. Herein, a series of novel pyrimidine structures as p97 inhibitors were designed and synthesized. After enzymatic evaluations, structure-activity relationships (SAR) were discussed in detailed. Among the screened compounds, derivative 35 showed excellent enzymatic inhibitory activity (IC50, 36 nM). The cellular inhibition results showed that compound 35 had good antiproliferative activity against the non-small cell lung cancer A549 cells (IC50, 1.61 μM). Liver microsome stability showed that the half-life of compound 35 in human liver microsome was 42.3 min, which was more stable than the control CB-5083 (25.8 min). The in vivo pharmacokinetic results showed that the elimination phase half-lives of compound 35 were 4.57 h for ig and 3.64 h for iv, respectively and the oral bioavailability was only 4.5%. These results indicated that compound 35 could be effective for intravenous treatment of non-small cell lung cancer.

AROMATIC DERIVATIVES, PREPARATION METHODS, AND MEDICAL USES THEREOF

The present disclosure relates generally to aromatic derivatives that are inhibitors of FGFR4 and are useful in treating FGFR4-associated diseases or conditions. Compositions containing the compounds of the present disclosure are also provided.

Discovery and Optimization of Glucose Uptake Inhibitors

Aerobic glycolysis, originally identified by Warburg as a hallmark of cancer, has recently been implicated in immune cell activation and growth. Glucose, the starting material for glycolysis, is transported through the cellular membrane by a family of glucose transporters (GLUTs). Therefore, targeting glucose transporters to regulate aerobic glycolysis is an attractive approach to identify potential therapeutic agents for cancers and autoimmune diseases. Herein, we describe the discovery and optimization of a class of potent, orally bioavailable inhibitors of glucose transporters, targeting both GLUT1 and GLUT3.

Preparation method of polymerase inhibitor used for tumor-related diseases

The invention belongs to the field of medicinal chemistry, and particularly relates to a preparation method of a terminal anchor polymerase inhibitor with a structure shown in a formula I. The prepared compound has certain inhibitory activity against both PARP1 and PARP2.

Polymerase inhibitor used for treating tumor-related diseases

The invention belongs to the field of medicinal chemistry, and particularly relates to a tankyrase inhibitor of a structure as shown in a formula I. The compound shows certain inhibiting activity to both PARP1 and PARP2.

HETEROCYLCOALKENYL DERIVATIVES USEFUL AS AGONISTS OF THE GPR120 AND / OR GPR40

The present invention is directed to heterocycloalkenyl derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the GPR120 and / or GPR40 receptors. 5 More particularly, the compound

Discovery of Orally Bioavailable and Liver-Targeted Hypoxia-Inducible Factor Prolyl Hydroxylase (HIF-PHD) Inhibitors for the Treatment of Anemia

We report herein the design and synthesis of a series of orally active, liver-targeted hypoxia-inducible factor prolyl hydroxylase (HIF-PHD) inhibitors for the treatment of anemia. In order to mitigate the concerns for potential systemic side effects, we

Tankyrase inhibitor

The invention belongs to the technical field of medicine and specifically relates to a tankyrase inhibitor represented as a general formula (I) and pharmaceutically acceptable salts, esters, solvated compounds or stereisomers of the tankyrase inhibitor, wherein R1, R2, X1, X2, Y1, Y2, Y3, Y4, Z, L, n and A are defined as in the description. The invention also relates to preparation methods of the compounds, pharmaceutical preparations and pharmaceutical compositions containing the compounds, and applications of the compounds and the pharmaceutically acceptable salts, esters, solvated compounds or the stereoisomers of the compounds in preparing medicines of curing and/or preventing cancers and related diseases which are mediated by tankyrase.

Tankyrase inhibitor

The invention belongs to the technical field of medicines and particularly relates to a tankyrase inhibitor shown in the general formula (I) and pharmaceutically acceptable salt, ester, solvates or stereisomers thereof, wherein R1, R2, R3, R4, R5, m, n, p, Z, L, X and Y are defined in the description. The invention also relates to a preparation of the compounds, a drug preparation and a drug composition containing the compounds and application of the compounds, the pharmaceutically acceptable salt, ester, solvates or stereisomers thereof in preparation of a drug for treating and/or preventing cancer mediated by tankyrase and relevant diseases.

NOVEL DIHYDROPYRANOPYRIMIDINONE DERIVATIVES, AND USE THEREOF

The present invention relates to a novel dihydropyranopyrimidinone derivative, a tautomer thereof, a stereoisomer thereof and their mixture, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating a tankyrase-related disease, which contains the same as an active ingredient.